Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients

BACKGROUND/AIM: Lamivudine (LAM) plus adefovir (ADV) combination therapy is clinically efficacious for treating chronic hepatitis B (CHB) patients in China, but no pharmacoeconomic evaluations of this strategy are available. The aim of this study was to examine the cost-effectiveness of LAM plus ADV...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chi, Ke, Weixia, Liu, Li, Gao, Yanhui, Yao, Zhenjiang, Ye, Xiaohua, Zhou, Shudong, Yang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780199/
https://www.ncbi.nlm.nih.gov/pubmed/27041994
http://dx.doi.org/10.2147/DDDT.S98200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780199/
https://www.ncbi.nlm.nih.gov/pubmed/27041994
http://dx.doi.org/10.2147/DDDT.S98200

Ejemplares similares